WO1999016885A1 - Recepteur de lymphocyte t tueur reconnaissant le vih - Google Patents
Recepteur de lymphocyte t tueur reconnaissant le vih Download PDFInfo
- Publication number
- WO1999016885A1 WO1999016885A1 PCT/JP1998/004345 JP9804345W WO9916885A1 WO 1999016885 A1 WO1999016885 A1 WO 1999016885A1 JP 9804345 W JP9804345 W JP 9804345W WO 9916885 A1 WO9916885 A1 WO 9916885A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- polypeptide
- cells
- dna
- cell
- killer
- Prior art date
Links
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 title claims abstract description 52
- 210000001239 CD8-positive, alpha-beta cytotoxic T lymphocyte Anatomy 0.000 title claims abstract description 50
- 108091008874 T cell receptors Proteins 0.000 title claims abstract description 50
- 241000725303 Human immunodeficiency virus Species 0.000 title claims description 38
- 210000004027 cell Anatomy 0.000 claims abstract description 152
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 108
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 99
- 229920001184 polypeptide Polymers 0.000 claims abstract description 97
- 239000013598 vector Substances 0.000 claims abstract description 32
- 241001465754 Metazoa Species 0.000 claims abstract description 19
- 230000009261 transgenic effect Effects 0.000 claims abstract description 13
- 206010061598 Immunodeficiency Diseases 0.000 claims abstract description 8
- 208000029462 Immunodeficiency disease Diseases 0.000 claims abstract description 8
- 230000007813 immunodeficiency Effects 0.000 claims abstract description 8
- 239000002259 anti human immunodeficiency virus agent Substances 0.000 claims abstract description 5
- 229940124411 anti-hiv antiviral agent Drugs 0.000 claims abstract description 5
- 150000001413 amino acids Chemical class 0.000 claims description 23
- 241000700605 Viruses Species 0.000 claims description 16
- 239000002773 nucleotide Substances 0.000 claims description 16
- 125000003729 nucleotide group Chemical group 0.000 claims description 16
- 108020003175 receptors Proteins 0.000 claims description 15
- 238000004519 manufacturing process Methods 0.000 claims description 9
- 230000006378 damage Effects 0.000 claims description 8
- 108010065155 Human Immunodeficiency Virus env Gene Products Proteins 0.000 claims description 6
- 241000713772 Human immunodeficiency virus 1 Species 0.000 claims description 5
- 125000003275 alpha amino acid group Chemical group 0.000 claims 3
- 238000000034 method Methods 0.000 abstract description 84
- 238000012258 culturing Methods 0.000 abstract description 13
- 102000006707 alpha-beta T-Cell Antigen Receptors Human genes 0.000 abstract description 4
- 108010087408 alpha-beta T-Cell Antigen Receptors Proteins 0.000 abstract description 4
- 239000000470 constituent Substances 0.000 abstract description 2
- 230000002459 sustained effect Effects 0.000 abstract 1
- 108020004414 DNA Proteins 0.000 description 63
- 108090000623 proteins and genes Proteins 0.000 description 56
- 102100040029 Zinc finger protein 197 Human genes 0.000 description 34
- 210000001744 T-lymphocyte Anatomy 0.000 description 30
- 239000002299 complementary DNA Substances 0.000 description 30
- 238000011830 transgenic mouse model Methods 0.000 description 30
- 241000699660 Mus musculus Species 0.000 description 27
- 239000002609 medium Substances 0.000 description 27
- 241000588724 Escherichia coli Species 0.000 description 25
- 108020004999 messenger RNA Proteins 0.000 description 25
- 108091007433 antigens Proteins 0.000 description 22
- 102000036639 antigens Human genes 0.000 description 22
- 241000699670 Mus sp. Species 0.000 description 21
- 230000014509 gene expression Effects 0.000 description 18
- 239000000243 solution Substances 0.000 description 18
- 239000000427 antigen Substances 0.000 description 17
- 239000013604 expression vector Substances 0.000 description 16
- 235000018102 proteins Nutrition 0.000 description 16
- 102000004169 proteins and genes Human genes 0.000 description 16
- 241000699666 Mus <mouse, genus> Species 0.000 description 13
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 12
- 230000000295 complement effect Effects 0.000 description 12
- 102000005962 receptors Human genes 0.000 description 12
- 230000027455 binding Effects 0.000 description 11
- 230000001472 cytotoxic effect Effects 0.000 description 11
- 230000000638 stimulation Effects 0.000 description 11
- 210000004408 hybridoma Anatomy 0.000 description 10
- 239000013612 plasmid Substances 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 241000238631 Hexapoda Species 0.000 description 9
- 206010035226 Plasma cell myeloma Diseases 0.000 description 9
- 238000010367 cloning Methods 0.000 description 9
- 208000015181 infectious disease Diseases 0.000 description 9
- 201000000050 myeloid neoplasm Diseases 0.000 description 9
- 238000003757 reverse transcription PCR Methods 0.000 description 9
- 102000004190 Enzymes Human genes 0.000 description 8
- 108090000790 Enzymes Proteins 0.000 description 8
- 102100034349 Integrase Human genes 0.000 description 8
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 8
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- 238000005516 engineering process Methods 0.000 description 8
- 244000005700 microbiome Species 0.000 description 8
- 210000004989 spleen cell Anatomy 0.000 description 8
- 210000004102 animal cell Anatomy 0.000 description 7
- 238000009396 hybridization Methods 0.000 description 7
- 238000000338 in vitro Methods 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 6
- -1 315 (1985) Proteins 0.000 description 6
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 238000005119 centrifugation Methods 0.000 description 6
- 239000012634 fragment Substances 0.000 description 6
- 230000031942 natural killer cell mediated cytotoxicity Effects 0.000 description 6
- 239000008188 pellet Substances 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- 235000002639 sodium chloride Nutrition 0.000 description 6
- 241000701447 unidentified baculovirus Species 0.000 description 6
- 101710091045 Envelope protein Proteins 0.000 description 5
- 108091034117 Oligonucleotide Proteins 0.000 description 5
- 101710188315 Protein X Proteins 0.000 description 5
- 241000700159 Rattus Species 0.000 description 5
- 238000000246 agarose gel electrophoresis Methods 0.000 description 5
- 229910052799 carbon Inorganic materials 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 210000002950 fibroblast Anatomy 0.000 description 5
- 238000003018 immunoassay Methods 0.000 description 5
- 238000002955 isolation Methods 0.000 description 5
- 210000004698 lymphocyte Anatomy 0.000 description 5
- 238000010369 molecular cloning Methods 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 208000030507 AIDS Diseases 0.000 description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- 206010003445 Ascites Diseases 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- 102000009410 Chemokine receptor Human genes 0.000 description 4
- 108050000299 Chemokine receptor Proteins 0.000 description 4
- 241000701022 Cytomegalovirus Species 0.000 description 4
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 4
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 4
- 230000003321 amplification Effects 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 210000000628 antibody-producing cell Anatomy 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 239000012228 culture supernatant Substances 0.000 description 4
- 235000013601 eggs Nutrition 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 108020001507 fusion proteins Proteins 0.000 description 4
- 102000037865 fusion proteins Human genes 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- SEOVTRFCIGRIMH-UHFFFAOYSA-N indole-3-acetic acid Chemical compound C1=CC=C2C(CC(=O)O)=CNC2=C1 SEOVTRFCIGRIMH-UHFFFAOYSA-N 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 210000003292 kidney cell Anatomy 0.000 description 4
- 238000010841 mRNA extraction Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 238000003199 nucleic acid amplification method Methods 0.000 description 4
- 102000039446 nucleic acids Human genes 0.000 description 4
- 108020004707 nucleic acids Proteins 0.000 description 4
- 150000007523 nucleic acids Chemical class 0.000 description 4
- 235000000346 sugar Nutrition 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 244000063299 Bacillus subtilis Species 0.000 description 3
- 235000014469 Bacillus subtilis Nutrition 0.000 description 3
- 241000186146 Brevibacterium Species 0.000 description 3
- 101710149870 C-C chemokine receptor type 5 Proteins 0.000 description 3
- 241000255925 Diptera Species 0.000 description 3
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 3
- 239000012980 RPMI-1640 medium Substances 0.000 description 3
- 102000006382 Ribonucleases Human genes 0.000 description 3
- 108010083644 Ribonucleases Proteins 0.000 description 3
- 238000002105 Southern blotting Methods 0.000 description 3
- 108700042075 T-Cell Receptor Genes Proteins 0.000 description 3
- 108700019146 Transgenes Proteins 0.000 description 3
- 241000700618 Vaccinia virus Species 0.000 description 3
- 238000001042 affinity chromatography Methods 0.000 description 3
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 239000000975 dye Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- 239000012894 fetal calf serum Substances 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 230000003053 immunization Effects 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 230000002611 ovarian Effects 0.000 description 3
- 210000001672 ovary Anatomy 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 239000012521 purified sample Substances 0.000 description 3
- 230000009257 reactivity Effects 0.000 description 3
- 239000011347 resin Substances 0.000 description 3
- 229920005989 resin Polymers 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 210000001541 thymus gland Anatomy 0.000 description 3
- 230000005030 transcription termination Effects 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- 241000255789 Bombyx mori Species 0.000 description 2
- 108700031361 Brachyury Proteins 0.000 description 2
- 102100035875 C-C chemokine receptor type 5 Human genes 0.000 description 2
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 2
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 102000014914 Carrier Proteins Human genes 0.000 description 2
- 108010078791 Carrier Proteins Proteins 0.000 description 2
- 241000282552 Chlorocebus aethiops Species 0.000 description 2
- 229920002271 DEAE-Sepharose Polymers 0.000 description 2
- 241000588722 Escherichia Species 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N Glutamine Chemical compound OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 238000009004 PCR Kit Methods 0.000 description 2
- 229920002684 Sepharose Polymers 0.000 description 2
- 235000019764 Soybean Meal Nutrition 0.000 description 2
- 241000256251 Spodoptera frugiperda Species 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 230000024932 T cell mediated immunity Effects 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 241000255993 Trichoplusia ni Species 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 2
- 235000011130 ammonium sulphate Nutrition 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 210000000612 antigen-presenting cell Anatomy 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 239000013592 cell lysate Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000012149 elution buffer Substances 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 230000001605 fetal effect Effects 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 238000002523 gelfiltration Methods 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 210000002443 helper t lymphocyte Anatomy 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 239000003617 indole-3-acetic acid Substances 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 238000007857 nested PCR Methods 0.000 description 2
- 230000003472 neutralizing effect Effects 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 229920002523 polyethylene Glycol 1000 Polymers 0.000 description 2
- 229940113116 polyethylene glycol 1000 Drugs 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- XOJVVFBFDXDTEG-UHFFFAOYSA-N pristane Chemical compound CC(C)CCCC(C)CCCC(C)CCCC(C)C XOJVVFBFDXDTEG-UHFFFAOYSA-N 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 238000005185 salting out Methods 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- 238000002741 site-directed mutagenesis Methods 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- 239000004455 soybean meal Substances 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000012916 structural analysis Methods 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- LJRDOKAZOAKLDU-UDXJMMFXSA-N (2s,3s,4r,5r,6r)-5-amino-2-(aminomethyl)-6-[(2r,3s,4r,5s)-5-[(1r,2r,3s,5r,6s)-3,5-diamino-2-[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-hydroxycyclohexyl]oxy-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]oxyoxane-3,4-diol;sulfuric ac Chemical compound OS(O)(=O)=O.N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO LJRDOKAZOAKLDU-UDXJMMFXSA-N 0.000 description 1
- LFRDGHVRPSURMV-YFKPBYRVSA-N (4s)-4,5-dihydroxypentanal Chemical compound OC[C@@H](O)CCC=O LFRDGHVRPSURMV-YFKPBYRVSA-N 0.000 description 1
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- HMUNWXXNJPVALC-UHFFFAOYSA-N 1-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C(CN1CC2=C(CC1)NN=N2)=O HMUNWXXNJPVALC-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
- ASJSAQIRZKANQN-CRCLSJGQSA-N 2-deoxy-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)CC=O ASJSAQIRZKANQN-CRCLSJGQSA-N 0.000 description 1
- YLZOPXRUQYQQID-UHFFFAOYSA-N 3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]propan-1-one Chemical compound N1N=NC=2CN(CCC=21)CCC(=O)N1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F YLZOPXRUQYQQID-UHFFFAOYSA-N 0.000 description 1
- TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 1
- LPXQRXLUHJKZIE-UHFFFAOYSA-N 8-azaguanine Chemical compound NC1=NC(O)=C2NN=NC2=N1 LPXQRXLUHJKZIE-UHFFFAOYSA-N 0.000 description 1
- 229960005508 8-azaguanine Drugs 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- 239000004254 Ammonium phosphate Substances 0.000 description 1
- 241000272875 Ardeidae Species 0.000 description 1
- 241001367049 Autographa Species 0.000 description 1
- 241000201370 Autographa californica nucleopolyhedrovirus Species 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 241000193744 Bacillus amyloliquefaciens Species 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 241000588832 Bordetella pertussis Species 0.000 description 1
- 101000800130 Bos taurus Thyroglobulin Proteins 0.000 description 1
- 239000012619 Butyl Sepharose® Substances 0.000 description 1
- 102100037853 C-C chemokine receptor type 4 Human genes 0.000 description 1
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 description 1
- 108010039171 CC cytokine receptor-4 Proteins 0.000 description 1
- QLNSPJMIYWEWNF-UHFFFAOYSA-N CC(C)CCCC(C)CCCC(C)CCCC(C)C.CC(C)CCCC(C)CCCC(C)CCCC(C)C Chemical compound CC(C)CCCC(C)CCCC(C)CCCC(C)C.CC(C)CCCC(C)CCCC(C)CCCC(C)C QLNSPJMIYWEWNF-UHFFFAOYSA-N 0.000 description 1
- 108700012434 CCL3 Proteins 0.000 description 1
- 108010061299 CXCR4 Receptors Proteins 0.000 description 1
- 101100327917 Caenorhabditis elegans chup-1 gene Proteins 0.000 description 1
- 101100084503 Caenorhabditis elegans pas-3 gene Proteins 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 102000000013 Chemokine CCL3 Human genes 0.000 description 1
- 102000001327 Chemokine CCL5 Human genes 0.000 description 1
- 108010055166 Chemokine CCL5 Proteins 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 101100007328 Cocos nucifera COS-1 gene Proteins 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 241000766026 Coregonus nasus Species 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 241000186216 Corynebacterium Species 0.000 description 1
- 241000186226 Corynebacterium glutamicum Species 0.000 description 1
- 241001485655 Corynebacterium glutamicum ATCC 13032 Species 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 101710200158 DNA packaging protein Proteins 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 101150040523 EN gene Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241001452028 Escherichia coli DH1 Species 0.000 description 1
- 241001131785 Escherichia coli HB101 Species 0.000 description 1
- 241001646716 Escherichia coli K-12 Species 0.000 description 1
- 241001302584 Escherichia coli str. K-12 substr. W3110 Species 0.000 description 1
- 239000002714 Extracts of rosemary Substances 0.000 description 1
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 101150094690 GAL1 gene Proteins 0.000 description 1
- 101150092780 GSP1 gene Proteins 0.000 description 1
- 101150035751 GSP2 gene Proteins 0.000 description 1
- 102100021736 Galectin-1 Human genes 0.000 description 1
- 102100024637 Galectin-10 Human genes 0.000 description 1
- 101001011019 Gallus gallus Gallinacin-10 Proteins 0.000 description 1
- 101001011021 Gallus gallus Gallinacin-12 Proteins 0.000 description 1
- 101710160913 GemA protein Proteins 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 108010074032 HLA-A2 Antigen Proteins 0.000 description 1
- 102000025850 HLA-A2 Antigen Human genes 0.000 description 1
- 108010086377 HLA-A3 Antigen Proteins 0.000 description 1
- 101000646854 Haloarcula marismortui (strain ATCC 43049 / DSM 3752 / JCM 8966 / VKM B-1809) 30S ribosomal protein S11 Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000946860 Homo sapiens T-cell surface glycoprotein CD3 epsilon chain Proteins 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- 235000003332 Ilex aquifolium Nutrition 0.000 description 1
- 241000209027 Ilex aquifolium Species 0.000 description 1
- 241001138401 Kluyveromyces lactis Species 0.000 description 1
- 241000235058 Komagataella pastoris Species 0.000 description 1
- 241000023320 Luma <angiosperm> Species 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241001467578 Microbacterium Species 0.000 description 1
- 241000144155 Microbacterium ammoniaphilum Species 0.000 description 1
- 101710151805 Mitochondrial intermediate peptidase 1 Proteins 0.000 description 1
- 101100480715 Mus musculus Mapt gene Proteins 0.000 description 1
- 241001045988 Neogene Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 108010058846 Ovalbumin Proteins 0.000 description 1
- 241000237988 Patellidae Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 241000235648 Pichia Species 0.000 description 1
- 241001417524 Pomacanthidae Species 0.000 description 1
- 108010009736 Protein Hydrolysates Proteins 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 241000589774 Pseudomonas sp. Species 0.000 description 1
- 108091034057 RNA (poly(A)) Proteins 0.000 description 1
- 238000010240 RT-PCR analysis Methods 0.000 description 1
- 241000235070 Saccharomyces Species 0.000 description 1
- 241000235346 Schizosaccharomyces Species 0.000 description 1
- 241000235347 Schizosaccharomyces pombe Species 0.000 description 1
- 241000235005 Schwanniomyces occidentalis var. occidentalis Species 0.000 description 1
- 241000607720 Serratia Species 0.000 description 1
- 241000881765 Serratia ficaria Species 0.000 description 1
- 241000218654 Serratia fonticola Species 0.000 description 1
- 241000607717 Serratia liquefaciens Species 0.000 description 1
- 241000607715 Serratia marcescens Species 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 102100035794 T-cell surface glycoprotein CD3 epsilon chain Human genes 0.000 description 1
- 241001634922 Tausonia pullulans Species 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 241000223230 Trichosporon Species 0.000 description 1
- 208000035896 Twin-reversed arterial perfusion sequence Diseases 0.000 description 1
- 206010046865 Vaccinia virus infection Diseases 0.000 description 1
- 101100068489 Vicia faba AGPC gene Proteins 0.000 description 1
- 229940118555 Viral entry inhibitor Drugs 0.000 description 1
- 235000018936 Vitellaria paradoxa Nutrition 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000003916 acid precipitation Methods 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 238000005273 aeration Methods 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000012670 alkaline solution Substances 0.000 description 1
- 229940024546 aluminum hydroxide gel Drugs 0.000 description 1
- SMYKVLBUSSNXMV-UHFFFAOYSA-K aluminum;trihydroxide;hydrate Chemical compound O.[OH-].[OH-].[OH-].[Al+3] SMYKVLBUSSNXMV-UHFFFAOYSA-K 0.000 description 1
- 229960003896 aminopterin Drugs 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 229910000148 ammonium phosphate Inorganic materials 0.000 description 1
- 235000019289 ammonium phosphates Nutrition 0.000 description 1
- 238000005349 anion exchange Methods 0.000 description 1
- 238000005571 anion exchange chromatography Methods 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 239000012148 binding buffer Substances 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 238000010805 cDNA synthesis kit Methods 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 238000005277 cation exchange chromatography Methods 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- NFLRWRCXIJABMY-UHFFFAOYSA-M cesium diaminomethylideneazanium 2,2,2-trifluoroacetate thiocyanate Chemical compound [Cs+].[S-]C#N.NC(N)=N.OC(=O)C(F)(F)F NFLRWRCXIJABMY-UHFFFAOYSA-M 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000011098 chromatofocusing Methods 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229910000365 copper sulfate Inorganic materials 0.000 description 1
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 1
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 1
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 1
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 1
- NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000003398 denaturant Substances 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 238000011033 desalting Methods 0.000 description 1
- MNNHAPBLZZVQHP-UHFFFAOYSA-N diammonium hydrogen phosphate Chemical compound [NH4+].[NH4+].OP([O-])([O-])=O MNNHAPBLZZVQHP-UHFFFAOYSA-N 0.000 description 1
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 235000019797 dipotassium phosphate Nutrition 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 238000005868 electrolysis reaction Methods 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 108700004025 env Genes Proteins 0.000 description 1
- 101150030339 env gene Proteins 0.000 description 1
- DNJIEGIFACGWOD-UHFFFAOYSA-N ethyl mercaptane Natural products CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000011790 ferrous sulphate Substances 0.000 description 1
- 235000003891 ferrous sulphate Nutrition 0.000 description 1
- 125000005519 fluorenylmethyloxycarbonyl group Chemical group 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000012215 gene cloning Methods 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 229940027941 immunoglobulin g Drugs 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- 238000001155 isoelectric focusing Methods 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000000155 isotopic effect Effects 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- XIXADJRWDQXREU-UHFFFAOYSA-M lithium acetate Chemical compound [Li+].CC([O-])=O XIXADJRWDQXREU-UHFFFAOYSA-M 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000000527 lymphocytic effect Effects 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- GVALZJMUIHGIMD-UHFFFAOYSA-H magnesium phosphate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O GVALZJMUIHGIMD-UHFFFAOYSA-H 0.000 description 1
- 239000004137 magnesium phosphate Substances 0.000 description 1
- 229910000157 magnesium phosphate Inorganic materials 0.000 description 1
- 229960002261 magnesium phosphate Drugs 0.000 description 1
- 235000010994 magnesium phosphates Nutrition 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 229940099596 manganese sulfate Drugs 0.000 description 1
- 239000011702 manganese sulphate Substances 0.000 description 1
- 235000007079 manganese sulphate Nutrition 0.000 description 1
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 235000013379 molasses Nutrition 0.000 description 1
- 239000003147 molecular marker Substances 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 101150091879 neo gene Proteins 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 238000011580 nude mouse model Methods 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 229940092253 ovalbumin Drugs 0.000 description 1
- 210000003101 oviduct Anatomy 0.000 description 1
- 101150019841 penP gene Proteins 0.000 description 1
- 229960001639 penicillamine Drugs 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 229940066827 pertussis vaccine Drugs 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 150000008300 phosphoramidites Chemical class 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- QVLTXCYWHPZMCA-UHFFFAOYSA-N po4-po4 Chemical compound OP(O)(O)=O.OP(O)(O)=O QVLTXCYWHPZMCA-UHFFFAOYSA-N 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 229940125415 protein degrader Drugs 0.000 description 1
- 210000001938 protoplast Anatomy 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 239000003161 ribonuclease inhibitor Substances 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000009518 sodium iodide Nutrition 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 210000002325 somatostatin-secreting cell Anatomy 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 230000010415 tropism Effects 0.000 description 1
- 208000007089 vaccinia Diseases 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0337—Animal models for infectious diseases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Definitions
- DNA encoding a polypeptide capable of hybridizing under stringent conditions and capable of specifically damaging a cell infected with a human immunodeficiency virus is the above-mentioned (8) or (9).
- DNA as a probe means DNA obtained by colony hybridization, plaque hybridization, or Southern blot hybridization, etc.
- DNA derived from colonies or plaques After performing hybridization at 65 ° C in the presence of 0.7 to 1.OM NaCl using a filter immobilized with, 0.1 to 2 times concentration of SSC (saline-sodium citrate) solution Wash the filter at 65 ° C using a 1x concentration of SSC solution consisting of 15 OmM sodium salt and 15 mM sodium citrate. It can be mentioned D N A that can be more identified.
- SSC saline-sodium citrate
- polypeptide according to any one of (1) to (7), wherein the polypeptide is a polypeptide having a human-type constant region site.
- the spleen of the immunized animal is removed, and erythrocyte removal is performed to obtain sensitized lymphocytes.
- sensitized lymphocytes antigen-expressing or antigen-bound antigen-presenting cells, fibroblasts, etc., irradiated or treated with mitomycin-1C are used.
- these cells are syngeneic with the immune cells.
- a P18-specific killer T cell clone can be established.
- the killer T cell clones that damage HIV-infected cells of the present invention include RT_1, RT-2, RT-3 and the like.
- Methods for confirming T cells include FACScan using an antibody against a molecular marker expressed on the cell surface.
- T cell ⁇ receptor is a heterodimer protein in which ⁇ -chain and / 3 chain polypeptide are formed by disulfide bonds.
- the receptor forms a complex with CD3 and is expressed on the surface of ⁇ cells.
- Specific ⁇ cell ⁇ (3 receptors are composed of a number of different V- (D) -J-C regions, The other is thought to be defined by the amino acid sequence of the V region, and the specificity for foreign substances is mainly defined by the amino acid sequence of the D and J regions. Therefore, as a method for identifying a T cell receptor gene from a P18-specific killer T cell clone, the V region of the ⁇ . Chain and i3 chain of the T cell receptor was determined, and the entire gene sequence was identified from those results. I do.
- guanidine thiocyanate-cesium trifluoroacetate method As methods for preparing total RNA from T cell clones, guanidine thiocyanate-cesium trifluoroacetate method [Methods in Enzyraology, 154, 3 (1987)], acid-based guanidine thiocinone phenol The Holm (AGPC) method [Analytic al Biochemistry, 162, 156 (1987), Experimental Medicine 9, 1937 (1991)] and the like can be used.
- Methods for preparing mRNA as poly (A) + RNA from total RNA include oligo (dT) -immobilized cellulose column method (molecular cloning, 2nd edition) and a method using oligo dT latex. .
- a fragment obtained by amplifying a part of cDNA by a method using PCR [PCR Protocols, Academic Press (1990)] using primers based on a nucleotide sequence that has been partially identified, Oligonucleotides based on the known nucleotide sequence can be used.
- a primer prepared based on the base sequence can be used as the primer.
- CDNA is synthesized from mRNA from the cDNA clone having the DNA of the present invention selected as described above, according to the method described above.
- the nucleotide sequence of DNA obtained by the above method can be obtained by digesting the DNA fragment as it is or by using an appropriate restriction enzyme or the like and then incorporating the DNA fragment into a vector by a conventional method. Sanger) et al. [Proc. Natl. Acad. Sci. USA, 74, 5463 (1977)] or Perkin Elmer: 373A DNA Sequencer, Pharmacia, Lycoa
- the desired DNA can be prepared.
- the DNA synthesizer include a DNA synthesizer manufactured by Shimadzu Corporation using the thiophosphite method, and a DNA synthesizer mode1392 manufactured by Perkin'Elma Inc. using the phosphoramidite method.
- nucleotide sequence database such as GenBank, EMBL and DDBJ using a homology search program such as BLAST.
- the homology is searched by searching an amino acid sequence database such as GenPept, PIR, Swiss-Prot using a homology search program such as FASTA or FrameSearch. Existing genes with gender can be searched.
- a recombinant vector in which the DNA of the present invention is inserted downstream of a promoter of an appropriate expression vector is constructed, and the vector is introduced into a host cell to thereby express a polypeptide expressing the polypeptide of the present invention.
- the polypeptide of the present invention can be produced.
- any cells that can express the target gene such as bacteria, yeast, animal cells, insect cells, and plant cells
- a transformant obtained by introducing the recombinant vector into which the DNA of the present invention has been inserted into peripheral blood T cells of a healthy person can be used for gene therapy of HIV-infected patients.
- those capable of autonomous replication in the host cell or integration into the chromosome and containing a promoter at a position where the DNA of the present invention can be transcribed are used.
- the T cell receptor component gene expression vector of the present invention is capable of autonomous replication in a prokaryote, and has a promoter, a ribosome binding sequence, and a DNA of the present invention.
- transcription termination sequence Force S preferably more configuration recombinant vector.
- a gene that controls a promoter may be included.
- expression vectors examples include PSE280 (manufactured by Invitrogen), P GEMEX-1 (manufactured by Promega), pQE-8 (manufactured by QIAGEN), pKYPIO
- Any promoter can be used as long as it can be expressed in a host cell. If for example, E. coli as a host, I £ E promoter (P ££), cited lac Buromota one, P L promoter one coater, T7 promoter, such as P R promoter, the promoter Chief derived from Escherichia coli or phage, etc. be able to. Alternatively, a promoter in which two Ptrps are arranged in tandem (P ⁇ £ 2 x2), a promoter designed and modified artificially such as a tac promoter, a T7 lac promoter, a let I promoter, etc. can also be used. When Bacillus subtilis is used as a host, examples thereof include promoters of Bacillus subtilis SP ⁇ 1 and SP ⁇ 2, penP promoter and the like.
- the ribosome binding sequence it is preferable to use a plasmid in which the distance between the Shine-Dalgarno sequence and the initiation codon is adjusted to an appropriate distance (for example, 6 to 18 bases).
- a transcription termination sequence is not necessarily required for expression of the DNA of the present invention. It is preferable to arrange a transcription termination sequence immediately below a force structural gene.
- Host cells include microorganisms belonging to the genus Escherichia, Serratia, Bacillus, Brevibacterium, Corynebacterium, Microbacterium, Pseudomonas, etc., for example, Escherichia coli XLl-Blue Escherichia coli XL2-Blue Escherichia coli DH1 Escherichia coli MC1000 Escherichia coli KY3276 Escherichia coli W1485 Escherichia coli JM109 Escherichia coli HB101 Escherichia coli No. 49 Escherichia coli W3110 Escherichia coli NY49 Serratia ficaria ⁇ Serratia fonticola x Serratia liquefaciens
- Any method for introducing the recombinant vector can be used as long as it is a method for introducing DNA into the host cell.
- a method using calcium ions [Proc. Natl. Acad. Sci. USA, 69 , 2110 (1972)], the protoplast method (JP-A-63-248394), the electrolysis method [Gene, 17, 107 (1982), Molecular & General Genetics, 168, HI (1979)]. it can.
- Examples of the plasmid containing the DNA encoding the component polypeptide of the killer T cell receptor of the present invention include, for example, pH-RTla containing DNA encoding the ⁇ chain of killer T cell receptor, killer T cell Escherichia coli TGl / pH-RTla, which is Escherichia coli containing Plasmid K PH-RTIa, and Escherichia, which is Escherichia coli containing Plasmid K PH-RTI ⁇ coli TGI / pH-RTl0 was published on August 26, 1997 by the National Institute of Bioscience and Human-Technology Agency of Industrial Science and Technology (Ibaraki, Japan).
- FERM BP-6078 and FERM BP-6079 have been deposited with Higashi 1-3-1 Higashi, Tsukuba City, Prefecture, respectively.
- YE Pl3 ATCC37115
- YEp24 ATCC37051
- YC P 50 ATCC37419
- Any promoter can be used as long as it can be expressed in yeast strains. Examples thereof include PH05 promoter, PGK promoter, GAP promoter, ADH promoter, gal1, promoter, gal10 promoter, and heat shock. Promoters such as polypeptide promoter, MFal promoter, CUP 1 promoter and the like can be mentioned.
- host cells examples include yeast strains belonging to the genera Saccharomyces, Schizosaccharomyces, Kluybium mycetes, Trichosporon, Schizinomyces, Pichia, etc.
- Saccharomyces cerevisiae examples include yeast strains belonging to the genera Saccharomyces, Schizosaccharomyces, Kluybium mycetes, Trichosporon, Schizinomyces, Pichia, etc.
- any method can be used as long as it is a method for introducing DNA into yeast.
- electroporation Methods in Enzymology, 194, 182 (1990)
- spheroplast method Proc. Natl. Acad. Sci. USA, 81, 4889 (1984)]
- lithium acetate method Journal of Bacteriology, 153, 163 (1983)] and the like.
- expression vectors include PCD NA I / Amp (manufactured by Invitrogen), pc DNAI, pAMoERC3Sc, pCD M8 [Nature, 329, 840 (1987)], pAGE 107 (JP-A-3-22979,
- any promoter can be used as long as it can be expressed in animal cells.
- the promoter of the cytomegalovirus (CMV) IE (i-hiddenate early) gene, the SV40 early promoter or the metallotionin promoter can be used.
- the EN gene of human C A sensor may be used with the promoter.
- animal cells examples include mouse myeloma cells, rat myeloma cells, mouse hybridoma cells, Namalwa cells or Namalwa KJM-1 cells that are human cells, human fetal kidney cells, and human cells.
- Leukemia cells African green monkey kidney cells, Chinese hamster cells such as CH0 cells, HBT5637 (JP-A-63-299), and the like.
- Mouse 'myeloma cells include SP2 / 0 and NS0
- rat's myeloma cells include YB2 / 0, etc.
- human fetal kidney cells include HEK293 (ATCC: CR1573)
- human leukemia cells include BALL- Examples of African green monkey kidney cells include COS-1 and COS-7.
- Any method for introducing a recombinant vector can be used as long as it is a method for introducing DNA into animal cells.
- the electoporation method can be used.
- Baculovirus Exclusion 'Vectors a laboratory' manual [Baculovirus
- a recombinant gene transfer vector and a baculovirus are co-transfected into insect cells to obtain a recombinant virus in an insect cell culture supernatant, and the recombinant virus is further infected into insect cells to express the polypeptide. be able to.
- Examples of the gene transfer vector used in the method include PVL1392, PVL1393, pBlueBacIII (all manufactured by Invitrogen) and the like.
- Baculoviruses are, for example, viruses that infect night roth moths Autographa californi force, Nuclea polyhedrosis. Virus
- insect cells ovarian cells of Spodoptera frugiperda, ovary cells of Trichoplusia ni, cultured cells derived from silkworm ovary, and the like can be used.
- the ovarian cells of Spodoptera frugiperda include Sf9 and Sf21 (Baculovirus Expression, Solution Vectors, A Laboratory 'Manual) etc.
- the ovarian cells of Trichoplusia ni are High 5, BTI-TN-5B1-4 (Invitrogen) And cultured cells derived from the silkworm ovary, such as Botnbyx mori N4.
- Examples of a method of co-introducing the recombinant gene introduction vector and the baculovirus into insect cells for preparing a recombinant virus include a calcium phosphate method.
- a sugar or a sugar chain-added polypeptide When expressed by yeast, animal cells or insect cells, a sugar or a sugar chain-added polypeptide can be obtained.
- the T-cell receptor constituent polypeptide can be expressed in vivo in a patient.
- the method for culturing the transformant of the present invention in a medium is performed according to a usual method used for culturing a host.
- a culture medium for culturing a transformant obtained by using a microorganism such as Escherichia coli or yeast as a host contains a carbon source, a nitrogen source, inorganic salts, and the like, which can be used by the microorganism, and efficiently cultivates the transformant.
- a natural medium or a synthetic medium may be used.
- Nitrogen sources include ammonia, ammonium chloride, ammonium sulfate, ammonium acetate, ammonium phosphate and other inorganic or organic acid ammonium salts or other nitrogen-containing compounds, as well as peptone, meat extract, yeast extract, and corn starch. Plyka, casein hydrolyzate, soybean meal, soybean meal hydrolyzate, various fermented cells or digests thereof are used.
- potassium phosphate monobasic, potassium phosphate dibasic, magnesium phosphate, magnesium sulfate, sodium chloride, ferrous sulfate, manganese sulfate, copper sulfate, calcium carbonate and the like are used as the inorganic substances.
- the cultivation is usually carried out at 15 to 40 ° C for 16 to 96 hours under aerobic conditions such as shaking culture or deep aeration stirring culture.
- the pH is maintained at 3.0 to 9.0.
- the pH is adjusted using an inorganic or organic acid, an alkaline solution, urea, calcium carbonate, ammonia, or the like.
- RPMI 1640 medium Eag 1e MEM medium or these mediums can be used.
- a medium to which fetal calf serum or the like is added is used.
- Cultures, 5% C 0 2 presence usually performed 3-7 days at 3 5 to 3 7 ° C, the culture if necessary, kanamycin, be added to the antibiotic penicillamine phosphorus in the medium Good.
- the polypeptide of the present invention can be produced as a fusion protein with another protein, and purified using affinity chromatography using a substance having an affinity for the fused protein.
- affinity chromatography using a substance having an affinity for the fused protein.
- the method of Low et al. Proc. Natl. Acad. Sci. USA, 86, 8227 (1989), Genes Develop., 4, 1288 (1990)] JP-A-05-336963, JP-A-06-823021
- the polypeptide of the present invention can be produced as a fusion protein with protein A, and purified by affinity chromatography using immunoglobulin G.
- Poribe peptide of the present invention F 1 produced as a fusion protein with ag peptide can be force s purified by Afi two tee one chromatography using anti F 1 ag antibody [Proc. Natl. Acad. Sci USA, 86, 8227 (1989), Genes Develop., 4, 1288 (1990)]. Further, the polypeptide can be purified by affinity chromatography using an antibody against the polypeptide itself.
- polypeptide of the present invention may be prepared based on amino acid sequence information of the polypeptide, such as Fmoc method (fluorenylmethyloxycarbonyl method), tBoc method (t-butyloxycarbonyl method) and the like. It can also be manufactured by the chemical synthesis method of (1).
- Chemical synthesis can also be performed using peptide synthesizers such as (Protein Technology Instrument), Synthecell-Vega, PerSeptive and Shimadzu.
- peptide synthesizers such as (Protein Technology Instrument), Synthecell-Vega, PerSeptive and Shimadzu.
- Structural analysis of the purified polypeptide of the present invention is described in a method commonly used in protein chemistry, for example, protein structural analysis for gene cloning (Hisashi Hirano, published by Tokyo Kagaku Dojin, 1993). The method can be implemented by the following method.
- a transgenic animal is an animal obtained by introducing a foreign gene into an animal at an early stage of its development.
- the production of transgenic mice is described below.
- the transgenic mice of the present invention are described in Hogan, B. et al. [Manupulating the mouse embryo. A laboratory manual. 2nd ed. 1994. Cold Spring Harbor Laboratory Press, New York. 96, 357-363 (1984)]. That is, after hormonally-treated female C57BL / 6 mice are mated, the fertilized eggs are removed, and the prepared transgene fragment not containing the vector portion is placed in a microglass pipe in the male pronucleus of the fertilized eggs. And microinjection. Transgenic mice are produced by transplanting several hundred surviving pseudopregnant female mice out of the obtained transgenic eggs into oviducts.
- an antibody that recognizes the polypeptide of the present invention can be prepared as follows.
- the protein obtained above is immunized as an antigen.
- the antigen may be administered subcutaneously, intravenously or intraperitoneally to the animal, but may be administered by binding a carrier protein having high antigenicity, or the antigen may be administered together with an appropriate adjuvant. Is preferred.
- Carrier proteins include keyhole limpet mosquito, keyhole lysine mossin, bovine serum albumin, and bovine thyroglobulin.
- Adjuvants include Freund's complete adjuvant (Co immediately lete Freund's Adjuvant), Aluminum hydroxide gel and B. pertussis vaccine. Examples of the immunized animal include non-human mammals such as rabbits, goats, mice aged 30 to 20 weeks, rats, and hamsters.
- the antigen is administered 3 to 10 times every 1 to 2 weeks after the first administration.
- the dosage of the antigen is preferably 50 to 100/1 g per animal.
- Blood is collected from the fundus venous plexus or tail vein of the immunized animal 3 to 7 days after each administration, and the reactivity of the serum with the antigen is determined by enzyme immunoassay [enzyme immunoassay (ELISA)]. Confirmed in the Medical Shoin Publishing (1976).
- a non-human mammal whose serum shows a sufficient antibody titer is used as a source of serum or antibody-producing cells.
- a monoclonal antibody is prepared by fusing the antibody-producing cells with myeloma cells derived from a non-human mammal to produce a hybridoma, and culturing the hybridoma or administering the hybridoma to an animal to cause the cells to become ascites tumor, It can be prepared by separating and purifying the culture solution or ascites.
- Antibody-producing cells are collected from spleen cells, lymph nodes, peripheral blood, and the like of a non-human mammal to which antigen has been administered.
- mice 8-azaguanine-resistant mice (derived from BALB / c) myeloma cell line P3-X63Ag8-Ul (P3-U1), a cell line obtained from mice [G. Kohler et al. ⁇ Journal ⁇ Journal 'Ebop Immunology. (Europ. J. Immunol.), 6, 511 (1976)], SP2 / 0-Agl4 (SP-2) [ ⁇ . Shulman et al .; Nature, 276 , 269 (1978)], P3-X63-Ag8653 (653) [JF Kearney et al .; Journal of Immunology, J.
- a cell-aggregating medium such as polyethylene glycol-1000 (PEG-1000) is added, and the cells are fused and suspended in a medium.
- PEG-1000 polyethylene glycol-1000
- MEM medium or PBS 1.83 g of sodium phosphate, 0.21 g of phosphate monophosphate, 7.65 g of salt, 1 liter of distilled water, pH 7.2
- a medium for suspending the fused cells a HAT medium ⁇ normal medium [1.5 mM glutamin, 5 ⁇ 10 " 5 2- in RPMI-1640 medium, so that only the desired fused cells can be selectively obtained.
- a part of the culture supernatant is removed, and a sample that reacts with the antigen protein but does not react with the non-antigen protein is selected by enzyme immunoassay. Subsequently, cloning is performed by the limiting dilution method, and those that have a stable and high antibody titer determined by enzyme immunoassay are selected as monoclonal antibody-producing hybridoma strains.
- the antigen protein or cells expressing the antigen protein are coated on a 96-well plate, and the hybridoma culture supernatant or purified antibody is reacted as the primary antibody.
- the plate After the first antibody reaction, the plate is washed and the second antibody is added.
- the second antibody is an antibody obtained by labeling an antibody capable of recognizing the immunoglobulin of the first antibody with biotin, an enzyme, a chemiluminescent substance, a radiation compound, or the like. Specifically, if a mouse was used for preparing the hybridoma, an antibody capable of recognizing mouse immunoglobulin is used as the second antibody.
- a reaction according to the substance labeled with the second antibody is performed, and the antibody is selected as a hybridoma that produces a monoclonal antibody that specifically reacts with the antigen.
- Monoclonal antibodies were cultured in a culture solution obtained by culturing Hypridoma cells or treated with pristane (0.5 ml of 2,6,10,14-tetramethylpentadecane (Pristane) was intraperitoneally administered and bred for 2 weeks).
- Monoclonal antibody-producing hybridoma cells can be intraperitoneally administered to mice or nude mice of 10 to 10 weeks of age to separate and purify the ascites from ascites cancer.
- Methods for separating and purifying monoclonal antibodies include centrifugation, salting out with 40-50% saturated ammonium sulfate, cabrylic acid precipitation, DEAE-Sepharose column, anion exchange column, protein A or G-column or gel filtration column. And the like, which may be performed alone or in combination. According to this method, an IgG or IgM fraction can be collected to obtain a purified monoclonal antibody.
- FIG. 1 shows the results of observing which peptides the established T cell clones RT-1, RT-2 and RT-3 recognize.
- Figure 2 shows that the established killer T cell clone RT-1 derived cells were 1) treated with complement alone, 2) treated with complement and anti-CD8 antibody, 3) treated with complement and anti-CD4 antibody, 4) 4 is a graph showing changes in cytotoxic activity when untreated.
- FIG. 3 shows the results of experiments examining the ability to perform S-specific recognition when P18 was presented with any class I HC molecule.
- Class I HC The KDL, in mice, the class I MHC molecules that present antigens may, K, D, consists regions of L, such in mouse B10 D2, K a, D a , that the L d Show.
- FIG. 4 shows the results obtained by agarose gel electrophoresis of V) 38.1 DNA obtained from the killed T cell clone RT-1 amplified by PCR.
- FIG. 5 shows the results of staining the T cell clone RT-1 with the anti-) 38.1 antibody and analyzing it using flow cytometry.
- FIG. 6 shows the results of confirming the Va 42Hll DNA obtained from the killer T cell clone RT-1 amplified by PCR by agarose gel electrophoresis.
- V region The 13-chain V region (hereinafter referred to as V region) of the mouse T cell receptor is one of V01-V (317). Therefore, based on the characteristic sequence of each 5 'end, A primer (CB04E; SEQ ID NO: 2) based on the designed primer group and the sequence of the mouse T cell receptor 3-chain C region (hereinafter referred to as the C0 region) commonly found in all
- RT-PCR was performed to amplify the clone-derived mRNA, and agarose gel electrophoresis of the obtained sample revealed that cDNA was amplified for the primer of V
- nested PCR was performed by combining a primer of the V] 38 subclass having a sequence different from that of the primer used above with the CB04E primer (SEQ ID NO: 2).
- Agarose gel Electrophoresis result amplification of the cDNA for the primer V 138.1 (SEQ ID NO: 3) was observed (Fig. 4) Furthermore, the RT- 1 anti V
- PCR buffer (xiO) 2 l dGTP, dATP, dTTP and dCTP 2 "each 1, RNase inhibitor 11 1, reverse Add 1 l of transcriptase, 3'-end primer (CB04E) 11 and mRNA 21 and mix with a voltex mixer for several seconds, then cycle at 42 ° C for 15 minutes, 99 at 5 minutes, 5 ° C for 5 minutes for 1 cycle As a result, one cycle of PCR was performed.
- PCR reaction solution a solution of Mg 2 4 1, PCR buffer (X10) 2 w 1, distilled water 65.51, and AmbriTac (AmpliTaq) DNA polymerase 0.51, and a 5′-end primer was added.
- the RT-1 derived mRNA, the primer (SEQ ID NO: 3) from the 5 'end of VJ38.1, the CB04E primer (SEQ ID NO: 2), and the 13-chain cDNA obtained using reverse transcriptase were 1.0% agarose gel containing the entire PCR reaction solution (501-100 / xl)
- Escherichia coli TGI / pH-RTl3 which has been transformed with Escherichia coli TGI / pH-RTl3 transfected with a plasmid pH-RTl / 3 containing DNA encoding the / 3 chain of the T-cell receptor, was released on August 26, 1997 by It has been deposited as FERM BP-6079 at the Institute of Biotechnology, Industrial Technology (1-3-1 Higashi, Tsukuba, Ibaraki, Japan).
- the ⁇ -chain V region (hereinafter referred to as the Va region) of mouse ⁇ cell receptor contains 12 V regions of Val-V ⁇ 12 and its subtypes; considerably more complex than the three chains It is said that about 80 types of V regions exist.
- a primer group designed based on each characteristic sequence and a primer of the C ⁇ region commonly found in all ⁇ chains (Exon-1 3Ca-R; SEQ ID NO: 5)
- mRNA derived from clone RT-1 was amplified by RT-PCR in the same manner as in Example 2-2. Although the experiment was repeated many times, amplification was not performed with any of the primers.
- the mRNA derived from RT-1 and Va42Hll (SEQ ID NO: 4), exon-1 3C ⁇ -R (SEQ ID NO: 5), and the a chain obtained using reverse transcriptase were used.
- cDNA was prepared, dideoxyribose labeled with a dye was added to the purified DNA, and the gene sequence was determined using a gene sequence analyzer.
- the nucleotide sequence of the T-cell receptor a-chain of RT-1 was Va42Hl-Ja25-Ca.
- the amino acid sequence of the T-cell receptor a chain of RT-1 is shown in SEQ ID NO: 9, and the nucleotide sequence is shown in SEQ ID NO: 8.
- the plasmid pH-RTla containing DNA encoding the a-chain of the T cell receptor was introduced.
- Escherichia coli TG1 / PH -RT1 ⁇ which is Escherichia coli, was submitted to the Ministry of International Trade and Industry, Ministry of Industry and Industry's Institute of Biotechnology and Industrial Technology on August 26, 1997 (1-1-3 Higashi, Tsukuba, Ibaraki, Japan). Deposited as FERM BP-6078.
- the T cell receptor a chain often has several subfamilies within the same V region, and it is known that a single T cell expresses two a chains. Even if the V region sequence near the VJC binding site detected by PCR is the same as V ⁇ 42 ⁇ 11, it may be a different subfamily of the same family, with a mutation at the 5 'upstream, and another completely different a-chain. It may have been expressed. Therefore, using the primers of any sequence at the Ca site (GSP-1 and GSP-2 in Fig. 7) and oligo dT primers, the cDNA of the upstream part of Ca from the RT-1 tnRNA was subjected to the 5 'RACE method.
- the V] 3 region does not have a subfamily like the V ⁇ region. Without determining the sequence using the 5 ′ RACE method, the VDJ region and the C region were amplified using RT-PCR, and each was joined to give a total length of V 08.1.
- Example 4 Transgenic mice expressing RT-1 T cell receptor 1. Preparation of transgenic mice expressing T cell receptor
- 3-DNA DNAs encoding T cell receptor ⁇ and / 3 chains
- transgenic mouse mosquitoes into which TCRa and TCR3 as the transgenes were respectively incorporated were obtained.
- These RTlTCRa- and RTCRiS- transgenic mice were combined with wild-type mice. Furthermore, they were crossed with Balb / c mice.
- For MHC genotypes should match the type having the original RT- 1 clone, as with back- Undo the H-2 d, to multiplying the RTlTCRa and RT1TCR0 is H- 2 a Therefore, to produce a mouse that expresses the background of H-2 a, and RTlTCRa] 3.
- TCRa chains and chains in the thus established transgenic mice was examined. The results are shown in FIG. Fluorescent staining with the anti-V (38 antibody (F23.1, manufactured by Pharmindin)) described above resulted in approximately 0% of the 0 chain in normal mice, but almost all CD8-positive cells in transgenic mice were V ] 38 + was found to be 5 ', whereas TCRa chain expression was not possible due to the absence of specific antibodies Therefore, mRNA expression was analyzed by RT-PCR using a primer corresponding to the binding region. RT-1 TCRa chain was hardly detectable in thymus and spleen cells of normal mice. It was found that the expression was considerably high in thymus and spleen cells of transgenic mice.
- Transgenic mice expressing only the TCR chain were analyzed. ⁇ Since antigen recognition by cells is performed by both the TCRa chain and the
- the repertoire of TCR ⁇ chains of T cells induced by in vitro stimulation was examined by RT-PCR.
- the TCR chain before stimulation with HIV gp160 the TCR ⁇ chain of T cells derived from transgenic mice was almost unchanged after stimulation with mosquito using a random ⁇ chain.
- CD8 + T cells were found to have a TCRa chain completely consistent with RT-1. That is, in the case of HIV gp16 ⁇ specific T cells, even if not ⁇ cells having both TCR ⁇
- a component polypeptide of a killer T cell receptor that specifically damages cells infected with human immunodeficiency virus, a DNA encoding the polypeptide, a vector containing the DNA, and a transformation transformed with the vector
- the present invention provides a body, a method for producing a polypeptide constituting a component of a T cell receptor, a transgenic animal expressing a polypeptide constituting a component of a T cell receptor, and an antibody against the polypeptide.
- the component polypeptide of the killer T cell receptor is useful as an anti-HIV agent.
- SEQ ID NO: 2 Oligonucleotide synthesized based on the sequence of C ⁇ 04 ⁇ SEQ ID NO: 3: V of cell receptor
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Environmental Sciences (AREA)
- Veterinary Medicine (AREA)
- Biodiversity & Conservation Biology (AREA)
- Animal Husbandry (AREA)
- Animal Behavior & Ethology (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Plant Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002304954A CA2304954A1 (en) | 1997-09-26 | 1998-09-28 | Killer t cell receptor recognizing human immunodeficiency virus |
EP98944273A EP1029918A4 (en) | 1997-09-26 | 1998-09-28 | HIV-RECOGNIZING T-KILLER T-LYMPHOCYTE RECEPTOR |
AU91865/98A AU9186598A (en) | 1997-09-26 | 1998-09-28 | Killer t cell receptor recognizing human immunodeficiency virus |
US09/509,347 US6511830B1 (en) | 1997-09-26 | 1998-09-28 | Killer T cell receptor recognizing human immunodeficiency virus |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP9/262536 | 1997-09-26 | ||
JP26253697 | 1997-09-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1999016885A1 true WO1999016885A1 (fr) | 1999-04-08 |
Family
ID=17377176
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP1998/004345 WO1999016885A1 (fr) | 1997-09-26 | 1998-09-28 | Recepteur de lymphocyte t tueur reconnaissant le vih |
Country Status (5)
Country | Link |
---|---|
US (1) | US6511830B1 (ja) |
EP (1) | EP1029918A4 (ja) |
AU (1) | AU9186598A (ja) |
CA (1) | CA2304954A1 (ja) |
WO (1) | WO1999016885A1 (ja) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7745180B2 (en) | 2002-04-24 | 2010-06-29 | Hitachi Chemical Co., Ltd. | Device and method for high-throughput quantification of mRNA from whole blood |
US20050277121A1 (en) * | 2004-06-11 | 2005-12-15 | Ambion, Inc. | Crude biological derivatives competent for nucleic acid detection |
US20060127377A1 (en) * | 2004-08-03 | 2006-06-15 | Stanislav Vukmanovic | T cell receptors with enhanced sensitivity recognition of antigen |
CN102220280A (zh) * | 2005-02-11 | 2011-10-19 | 新加坡科技研究局 | 增殖干细胞的方法 |
US20080064631A1 (en) * | 2006-01-13 | 2008-03-13 | Jeffrey Molldrem | T-cell receptors for use in diagnosis and therapy of cancers and autoimmune disease |
EP2102236B1 (en) * | 2007-01-12 | 2014-08-06 | Government of the United States of America, Represented by the Secretary, Department of Health and Human Services | GP100-specific T cell receptors and related materials and methods of use |
WO2011064664A2 (en) * | 2009-11-24 | 2011-06-03 | Chrontech Pharma Ab | T cell receptors specific for immunodominant ctl epitopes of hcv |
EP2550362B1 (en) | 2010-03-25 | 2017-01-04 | Oregon Health&Science University | Cmv glycoproteins and recombinant vectors |
CA2832109C (en) | 2011-06-10 | 2021-07-06 | Oregon Health & Science University | Cmv glycoproteins and recombinant vectors |
CA2789539A1 (en) | 2011-09-12 | 2013-03-12 | International Aids Vaccine Initiative | Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies |
US9402894B2 (en) | 2011-10-27 | 2016-08-02 | International Aids Vaccine Initiative | Viral particles derived from an enveloped virus |
EP2679596B1 (en) | 2012-06-27 | 2017-04-12 | International Aids Vaccine Initiative | HIV-1 env glycoprotein variant |
US20150065381A1 (en) | 2013-09-05 | 2015-03-05 | International Aids Vaccine Initiative | Methods of identifying novel hiv-1 immunogens |
US10058604B2 (en) | 2013-10-07 | 2018-08-28 | International Aids Vaccine Initiative | Soluble HIV-1 envelope glycoprotein trimers |
EP3069730A3 (en) | 2015-03-20 | 2017-03-15 | International Aids Vaccine Initiative | Soluble hiv-1 envelope glycoprotein trimers |
EP3072901A1 (en) | 2015-03-23 | 2016-09-28 | International Aids Vaccine Initiative | Soluble hiv-1 envelope glycoprotein trimers |
US9925258B2 (en) | 2015-10-02 | 2018-03-27 | International Aids Vaccine Initiative | Replication-competent VSV-HIV Env vaccines |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1985003947A1 (en) * | 1984-03-01 | 1985-09-12 | The Board Of Trustees Of The Leland Stanford Jr. U | T-cell receptor-specific for antigen polypeptides and related polynucleotides |
JPS61257998A (ja) * | 1984-10-31 | 1986-11-15 | マサチユ−セツツ・インステイテユ−ト・オブ・テクノロジ− | ヘテロダイマ性tリンパ球レセプタ |
JPS63276496A (ja) * | 1987-05-07 | 1988-11-14 | Kyowa Hakko Kogyo Co Ltd | 哺乳類T細胞受容体β鎖定常領域ポリペプチド |
JPH08149981A (ja) * | 1993-12-13 | 1996-06-11 | La Jolla Inst For Allergy & Immunology | T細胞α鎖による抗原特異的免疫制御の方法 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4874845A (en) * | 1984-06-13 | 1989-10-17 | Massachusetts Institute Of Technology | T lymphocyte receptor subunit |
ATE323756T1 (de) * | 1997-04-30 | 2006-05-15 | Hans Klingemann | Natürliche killerzelllinien und verfahren zu ihrer verwendung |
-
1998
- 1998-09-28 EP EP98944273A patent/EP1029918A4/en not_active Withdrawn
- 1998-09-28 WO PCT/JP1998/004345 patent/WO1999016885A1/ja not_active Application Discontinuation
- 1998-09-28 CA CA002304954A patent/CA2304954A1/en not_active Abandoned
- 1998-09-28 US US09/509,347 patent/US6511830B1/en not_active Expired - Lifetime
- 1998-09-28 AU AU91865/98A patent/AU9186598A/en not_active Abandoned
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1985003947A1 (en) * | 1984-03-01 | 1985-09-12 | The Board Of Trustees Of The Leland Stanford Jr. U | T-cell receptor-specific for antigen polypeptides and related polynucleotides |
JPS61257998A (ja) * | 1984-10-31 | 1986-11-15 | マサチユ−セツツ・インステイテユ−ト・オブ・テクノロジ− | ヘテロダイマ性tリンパ球レセプタ |
JPS63276496A (ja) * | 1987-05-07 | 1988-11-14 | Kyowa Hakko Kogyo Co Ltd | 哺乳類T細胞受容体β鎖定常領域ポリペプチド |
JPH08149981A (ja) * | 1993-12-13 | 1996-06-11 | La Jolla Inst For Allergy & Immunology | T細胞α鎖による抗原特異的免疫制御の方法 |
Non-Patent Citations (2)
Title |
---|
CEFAI D., ET AL.: "HUMAN IMMUNODEFICIENCY VIRUS-1 GLYCOPROTEINS GP 120 AND GP 160 SPECIFICALLY INHIBIT THE CD3/T CELL-ANTIGEN RECEPTOR PHOSPHOINOSITIDE TRANSDUCTION PATHWAY.", JOURNAL OF CLINICAL INVESTIGATION, AMERICAN SOCIETY FOR CLINICAL INVESTIGATION, US, vol. 86., no. 06., 1 January 1990 (1990-01-01), US, pages 2117 - 2124., XP002915343, ISSN: 0021-9738, DOI: 10.1172/JCI114950 * |
See also references of EP1029918A4 * |
Also Published As
Publication number | Publication date |
---|---|
EP1029918A1 (en) | 2000-08-23 |
EP1029918A4 (en) | 2003-01-02 |
AU9186598A (en) | 1999-04-23 |
CA2304954A1 (en) | 1999-04-08 |
US6511830B1 (en) | 2003-01-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1999016885A1 (fr) | Recepteur de lymphocyte t tueur reconnaissant le vih | |
US11041021B2 (en) | Car based immunotherapy | |
CN1110556C (zh) | 编码肿瘤排斥抗原前体mage-3的分离的核酸分子及其应用 | |
EP1249490B1 (en) | In vitro activation of cytotoxic T cells | |
US6046158A (en) | Unique dendritic cell-associated C-type lectins, dectin-1 and dectin-2; compositions and uses thereof | |
JP5148116B2 (ja) | 癌胎児性抗原融合タンパク質及びその使用 | |
AU739057B2 (en) | Novel polypeptide, novel DNA, and novel antibody | |
CN1468250A (zh) | 在转基因动物中产生人源化抗体 | |
JP2001503252A (ja) | タンパク質の高レベル発現 | |
JPWO2003104453A1 (ja) | 抗体作製方法 | |
KR19990087126A (ko) | 합성 사람 면역결핍 바이러스 유전자 | |
JP3144805B2 (ja) | ヒトTh2特異的タンパク質及びこれをコードする遺伝子(B19)並びにこれに関連する形質転換体、組換えベクター及びモノクローナル抗体 | |
US5962319A (en) | Human-Th1-specific protein, gene encoding the protein, transformants, recombinant vectors, and antibodies related to the gene | |
JP3450018B2 (ja) | コクシジウム症ワクチン | |
AU721579B2 (en) | Porcine retrovirus | |
JP2010252804A (ja) | ネコcd80、ネコcd86、ネコcd28およびネコctla−4核酸およびポリペプチド | |
JP2002171978A (ja) | 劇症c型肝炎ウイルス株の遺伝子 | |
JP3231262B2 (ja) | ヒトTh1特異的タンパク質及びこれをコードする遺伝子、並びにこれに関連する形質転換体、組換えベクター及び抗体 | |
KR20210084125A (ko) | 신규 사이토메갈로바이러스 dna 백신 컨스트럭트 및 그의 용도 | |
Timmusk et al. | The generation of monoclonal antibodies by genetic immunisation: antibodies against trout TCRα and IgL isotypes | |
JP2002513581A (ja) | ネコcd80、ネコctla−4またはネコcd86をコードする外来dnaを発現する組換えウイルスおよびその使用 | |
JP2008531032A (ja) | トランスジェニックマウス及び実験モデルとしての、その使用 | |
WO2000042180A1 (fr) | Nouvelle proteine | |
JP2997770B2 (ja) | ウシ由来c−Kitタンパク質に対するモノクローナル抗体とそれを用いた細胞分離法 | |
CN1468124A (zh) | 用于改变t细胞介导病理的方法和组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU BG BR CA CN CZ HU IL JP KR MX NO NZ PL RO SG SI SK UA US VN |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref document number: 2304954 Country of ref document: CA Ref country code: CA Ref document number: 2304954 Kind code of ref document: A Format of ref document f/p: F |
|
NENP | Non-entry into the national phase |
Ref country code: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09509347 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1998944273 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1998944273 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1998944273 Country of ref document: EP |